Naronapride is under clinical development by Renexxion and currently in Phase II for Corrosive Esophagitis (Erosive Esophagitis). According to GlobalData, Phase II drugs for Corrosive Esophagitis (Erosive Esophagitis) have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Naronapride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Likelihood of Approval and Phase Transition Success Rate Model - Naronapride in Corrosive Esophagitis (Erosive Esophagitis)

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Naronapride overview

Naronapride is under development for the treatment of multiple gastrointestinal disorders diabetic gastroparesis, erosive esophagitis,  nonresponsive symptomatic gastroesophageal reflux disease (PPI-nrsGERD) and gastrointestinal dysmotility in cystic fibrosis patients. The drug candidate is administered through oral route in the form of tablet. It acts by targeting serotonin type 4 (5HT4) and dopamine-2 receptor (D2). The drug candidate is designed based on Retrometabolic drug design technology.
The drug candidate was under development for the treatment of proton-pump inhibitor non-responsive symptomatic gastroesophageal reflux disease (“PPI-nrsGERD”), irritable bowel syndrome-constipation (IBS-C), chronic idiopathic constipation and functional dyspepsia.

Renexxion overview

Renexxion, LLC, a pharmaceutical company, develops oral 5HT4 agonist for gastrointestinal (GI) disorders. The company is headquartered in United States.

For a complete picture of Naronapride’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 12 April 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.